Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21843952 | 1.00 | EPHX1 (0.31) | EPHX1CA1CA2 | |
| SCHEMBL21917418 | 1.00 | EPHX1 (0.31) | EPHX1CA1CA2 | |
| SCHEMBL19708909 | 0.84 | ITGB3 (0.33) | EPHX1CA1CA2 | |
| SCHEMBL9714133 | 0.84 | ITGB3 (0.33) | EPHX1CA1CA2 | |
| Carbamic Acid SCHEMBL27983163 | 0.80 | ITGB3 (0.35) | — | |
| SCHEMBL30700134 | 0.80 | ALDH1A1 (0.41) | CA1CA2 | |
| SCHEMBL24377730 | 0.79 | — | — | |
| SCHEMBL3677560 | 0.79 | ALDH1A1 (0.39) | CA1CA2 | |
| SCHEMBL3677561 | 0.79 | ALDH1A1 (0.39) | CA1CA2 | |
| SCHEMBL10207210 | 0.79 | ALDH1A1 (0.39) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161442-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | EPHX1 2987/4885CA1 2203/4885CA2 4350/4885 |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | EPHX1 2987/4885CA1 2203/4885CA2 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.